MHK
46
12
ABT
54
-2
CVS
49
2
CHRW
39
3
CCL
33
2
AEP
34
5
PYPL
45
-2
KLAC
52
-5
PNW
57
2
HCA
35
-5
JCI
46
2
CPB
47
2
BMY
40
2
WAT
44
-4
CSCO
53
2
CLX
53
2
UHS
56
-3
CHD
59
-2
NOC
40
11
NTAP
60
-4
MHK
46
12
ABT
54
-2
CVS
49
2
CHRW
39
3
CCL
33
2
AEP
34
5
PYPL
45
-2
KLAC
52
-5
PNW
57
2
HCA
35
-5
JCI
46
2
CPB
47
2
BMY
40
2
WAT
44
-4
CSCO
53
2
CLX
53
2
UHS
56
-3
CHD
59
-2
NOC
40
11
NTAP
60
-4
Financhill
Back

Keros Therapeutics 10K Form

Sell
41

KROS
Keros Therapeutics

Last Price:
58.34
Seasonality Move:
-4.32%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KROS News And Ratings

See the #1 stock for the next 7 days that we like better than KROS

KROS Financial Statistics

Sales & Book Value

Annual Sales: $151K
Cash Flow: $-26M
Price / Cash Flow: 0
Annual Sales: $10.43
Price / Book: 6.39

Profitability

EPS (TTM): -5.20000
Net Income (TTM): $-152.99M
Gross Margin: --
Return on Equity: -48.21%
Return on Assets: -43.87%

Keros Therapeutics Earnings Forecast

Key Keros Therapeutics Financial Ratios

  • The Research & Development expenses have been 89,574.83% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of KROS is -101,319.21% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 1 years.

Keros Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KROS
CUSIP: 492327
Website: kerostx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 14.25
Quick Ratio: 13.63

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KROS Technical Analysis vs Fundamental Analysis

Sell
41
Keros Therapeutics (KROS) is a Sell

Is Keros Therapeutics a Buy or a Sell?